With GLP-1-based drugs ramping up staggering sales in obesity, and similar compounds in the clinic posting ever more impressive data, it is a brave company that chooses to pursue a non-incretin for the disorder. Shionogi & Co. Ltd. has learned that lesson the hard way, today disclosing disappointing results with its monoacylglycerol acyltransferase 2 inhibitor, S-309309.
Leftfield Obesity Mechanism Hurts Shionogi
When it comes to weight loss drug development, the sensible move is to follow the pack.
More from Clinical Trials
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from R&D
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.